ArQule (ARQL) -19.4% premarket after the biotech company is told by its Asian partner that it...

|By:, SA News Editor

ArQule (ARQL) -19.4% premarket after the biotech company is told by its Asian partner that it has temporarily suspended patient enrollment in its ongoing Phase 3 Attention trial on the recommendation of a safety review committee in Japan about reports of suspected cases of interstitial lung disease in the study.